Session Information

WCLC 2017

18th World Conference on Lung Cancer

Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan

Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.
Presentation Date(s):
- Oct 15 - 18, 2017
- Total Presentations: 2295
Register to Attend WCLC Return to WCLC 2017 Website Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Saturday
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18

Filter Results:

Show Only CME Accredited Sessions

20153

+
P1.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- 22619
  
  +
  
  P1.04-010 - CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia
  
  09:30 - 09:30 | Presenter: Shun Lu | Author(s): Li Zhang, Ying Cheng, Jie Wang, C. Wang, M. Wang, X. Li, Q. Wu, Yi-Long Wu
  Abstract
  
  Loading...
20163

+
P1.14 - Radiotherapy
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- 22778
  
  +
  
  P1.14-011 - An Esophagus-Sparing Technique to Limit Radiation Esophagitis in Locally Advanced NSCLC Treated by SIB-IMRT and Concurrent Chemotherapy
  
  09:30 - 09:30 | Presenter: Hui Liu | Author(s): L. Ma, Q. Li, L. Chen, M. Lin, B. Wang, Y. Hu, M. Liu, Li Zhang, Y. Huang, X. Deng, Y. Xia, B. Qiu
  Abstract
  
  Loading...
18890

+
GR 01 - What to Do at the Time of Progression on Targeted Therapy
- 11:00 - 12:30
- 10/16/2017
- Location: Room 303 + 304
- Type: Grand Rounds
- Track: Chemotherapy/Targeted Therapy
- Moderators:D. Kim, Lecia V Sequist
- 22860
  
  +
  
  GR 01.03 - First-Line Management of EGFR Mutant NSCLC
  
  11:10 - 11:30 | Presenter: Li Zhang
  Abstract
  
  Loading...
20168

+
P2.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- 23332
  
  +
  
  P2.04-003 - Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) Non–Small-Cell Lung Cancer Who Progressed on Crizotinib
  
  09:30 - 09:30 | Presenter: Li Zhang | Author(s): Junling Li, W. Zhong, Y. Hu, X. Liu, Z. Wang, Y. Zhao, J. Feng, J. Zhou, Y. Zhang, Yun Fan, G. Wu, F. Tan, L. Ding
  Abstract
  
  Loading...
20178

+
P2.14 - Radiotherapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- 23499
  
  +
  
  P2.14-004 - Comparable Local Controls after Twice-Daily and Once-Daily Chest Radiotherapy in Extensive Stage Small Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Bo Qiu | Author(s): Q. Li, W. Xie, Z. Hui, B. Wang, Y. Liang, J. Guo, Y. Zhou, M. Zhu, W. Shen, R. Duan, L. Chen, Li Zhang, H. Long, Hui Liu
  Abstract
  
  Loading...
20133

+
MA 08 - Supportive Care and Communication
- 11:00 - 12:30
- 10/17/2017
- Location: Room 511 + 512
- Type: Mini Oral
- Track: Nursing/Palliative Care/Ethics
- Moderators:E. Esposito-Nguyen, John McPhelim
- 23576
  
  +
  
  MA 08.02 - Efficacy of Single-Dose NEPA versus 3-Day Aprepitant Regimen for Prevention of CINV: A Phase 3 Lung Cancer Subset Analysis
  
  11:05 - 11:10 | Presenter: Shun Lu | Author(s): Li Zhang, A. Dechaphunkul, C. Lanzarotti, K. Jordan, M. Aapro
  Abstract
  
  Loading...
20132

+
MA 11 - Emerging Diagnostic/Biomarkers in NSCLC
- 11:00 - 12:30
- 10/17/2017
- Location: Room 313 + 314
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:M.I. Abdul Wahid, Martin Reck
- 23613
  
  +
  
  MA 11.03 - Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)
  
  11:10 - 11:15 | Presenter: Jie Wang | Author(s): Ying Cheng, Yi-Long Wu, T. An, H. Gao, K. Wang, Qing Zhou, Y. Hu, Yong Song, C. Ding, F. Peng, L. Liang, Y. Hu, C. Huang, Caicun Zhou, Y. Shi, Li Zhang, X. Ye, Y. Sun
  Abstract
  
  Loading...

Session Information

WCLC 2017

18th World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

P1.04 - Clinical Design, Statistics and Clinical Trials

+

P1.04-010 - CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia

+

P1.14 - Radiotherapy

+

P1.14-011 - An Esophagus-Sparing Technique to Limit Radiation Esophagitis in Locally Advanced NSCLC Treated by SIB-IMRT and Concurrent Chemotherapy

+

GR 01 - What to Do at the Time of Progression on Targeted Therapy

+

GR 01.03 - First-Line Management of EGFR Mutant NSCLC

+

P2.04 - Clinical Design, Statistics and Clinical Trials

+

P2.04-003 - Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) Non–Small-Cell Lung Cancer Who Progressed on Crizotinib

+

P2.14 - Radiotherapy

+

P2.14-004 - Comparable Local Controls after Twice-Daily and Once-Daily Chest Radiotherapy in Extensive Stage Small Cell Lung Cancer

+

MA 08 - Supportive Care and Communication

+

MA 08.02 - Efficacy of Single-Dose NEPA versus 3-Day Aprepitant Regimen for Prevention of CINV: A Phase 3 Lung Cancer Subset Analysis

+

MA 11 - Emerging Diagnostic/Biomarkers in NSCLC

+

MA 11.03 - Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)

Stay Connected